Nishat Samreen, Mueka Isaac N, Hassan Maria U, Pandey Ravi K, Lwin Bo B, Vashishta Apoorva, Nassar Sondos T
Clinical Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Clinical Research, NewYork-Presbyterian Queens, New York, USA.
Cureus. 2024 Jul 23;16(7):e65218. doi: 10.7759/cureus.65218. eCollection 2024 Jul.
Hypothyroidism, also known as underactive thyroid, is a condition where the thyroid gland does not produce enough thyroid hormone. Deficiency or lack of thyroid hormone causes patients to have a slower metabolism, which may lead to secondary medical issues such as weight gain, fatigue, depression, and increased cardiovascular risk. This systematic review aims to explore the effect of levothyroxine therapy on the lipid profile of hypothyroid patients. Through a comprehensive search, 3096 articles were retrieved using keywords such as Hypothyroidism, Levothyroxine, Lipid, Dyslipidemia, and Cholesterol from PubMed, PubMed Central, Google Scholar, and ScienceDirect databases. The Medical Subject Headings (MeSH) strategy was also leveraged to extensively search the PubMed database. Research articles that were published from the year 2020 until May 2024, including randomized control trials, observational studies, meta-analyses, systematic reviews, literature reviews, and case reports, were included in the research. Research papers published before 2020, written in languages other than English, and animal studies were excluded. The 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria were used in the design of the systematic review. Levothyroxine therapy is the treatment of choice in patients suffering from hypothyroidism, and based on our review, the treatment has a positive impact, leading to a significant decrease in total cholesterol, low-density lipoproteins, and triglyceride values in hypothyroid patients. The research highlights the importance of starting timely levothyroxine therapy in hypothyroid patients to maintain normal lipid levels and reduce the associated cardiovascular risk.
甲状腺功能减退症,也称为甲状腺功能低下,是一种甲状腺腺体产生的甲状腺激素不足的病症。甲状腺激素的缺乏或不足会导致患者新陈代谢减缓,这可能会引发如体重增加、疲劳、抑郁以及心血管疾病风险增加等继发性健康问题。本系统评价旨在探讨左甲状腺素治疗对甲状腺功能减退患者血脂水平的影响。通过全面检索,使用“甲状腺功能减退症”“左甲状腺素”“脂质”“血脂异常”和“胆固醇”等关键词,从PubMed、PubMed Central、谷歌学术和科学Direct数据库中检索到3096篇文章。还利用医学主题词(MeSH)策略对PubMed数据库进行了广泛检索。纳入研究的文章发表时间为2020年至2024年5月,包括随机对照试验、观察性研究、荟萃分析、系统评价、文献综述和病例报告。排除2020年以前发表的、非英文撰写的研究论文以及动物研究。本系统评价的设计采用了2020年系统评价和荟萃分析的首选报告项目(PRISMA)标准。左甲状腺素治疗是甲状腺功能减退症患者的首选治疗方法,根据我们的综述,该治疗具有积极影响,可使甲状腺功能减退患者的总胆固醇、低密度脂蛋白和甘油三酯值显著降低。该研究强调了甲状腺功能减退患者及时开始左甲状腺素治疗以维持正常血脂水平并降低相关心血管疾病风险的重要性。